Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab, formerly known as Numax(R), is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its first pivotal trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated a 26-percent reduction in RSV hospitalizations due to RSV and a 50-percent reduction in the incidence of RSV lower respiratory tract infections requiring outpatient management, its secondary endpoint.

About Synagis

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RS
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... --  Heska Corporation (NASDAQ: HSKA ) - ... advanced veterinary diagnostic and other specialty veterinary products , ... attend The Benchmark Company, LLC,s Micro Cap Discovery Conference on ... at The Palmer House Hilton, 17 E. Monroe Street, ... p.m. Please email hska@haydenir.com or contact your Benchmark ...
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... As annual open enrollment season begins for ... are available to answer questions and provide guidance ... 15 to December 7, Medicare beneficiaries have the ... enroll in a new plan, if they so ...
... Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the ... treatment of Alzheimer,s and other neurological diseases today issued ... Chairman and CEO. Dear Shareholder, ... you about pertinent corporate and industry developments contemporaneous with ...
Cached Medicine Technology:CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period 2Intellect Neurosciences Issues Letter to Shareholders 2Intellect Neurosciences Issues Letter to Shareholders 3Intellect Neurosciences Issues Letter to Shareholders 4Intellect Neurosciences Issues Letter to Shareholders 5Intellect Neurosciences Issues Letter to Shareholders 6Intellect Neurosciences Issues Letter to Shareholders 7Intellect Neurosciences Issues Letter to Shareholders 8Intellect Neurosciences Issues Letter to Shareholders 9
(Date:11/27/2014)... 2014 (HealthDay News) -- Thanksgiving meals can pose a ... diet, an expert says. Many traditional Thanksgiving dishes ... sauce -- are gluten-free, but "when it comes to ... be considered," Dr. Anca Safta, director of the Gluten ... Medical Center in North Carolina, said in a center ...
(Date:11/27/2014)... New York, NY (PRWEB) November 27, 2014 ... devoted to offering stylish, comfortable and high functioning compression socks, ... line. The newly-released socks use an innovative Gradient Pressure (TM) ... freshly oxygenated blood. , VIM & VIGR’s commitment to adding ... thought of as just functional recently caught the eye of ...
(Date:11/27/2014)... NV (PRWEB) November 27, 2014 Now ... shopping season has officially launched, Emassagechair.com has ... Cyber Monday Discount Event. , Negotiating on behalf ... with top massage chair brands, Emassagechair.com has generated significant ... best deals and biggest discounts yet. , Shoppers are ...
(Date:11/27/2014)... 2014 Two international trainers and lecturers ... will help one person with significant needs but limited ... and Dr. Mamaly Reshad of the Anacapa Dental Art ... a website devoted to helping dentist learn about using ... would be devoted to helping a patient who has ...
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “Wekho” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review ... locations instead of people. , An interesting new way to ... iOS and Android devices. It’s called Wekho and it’s ...
Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2
... ... , ... 2010 -- From self-published author Felicia J. Henderson comes a personal tale of despair, survival, ... book that will reach out to those who have experienced life’s trials and never lost ...
... ... volcano Eyjafjallajökull has not only interfered in the air traffic around the globe. ... the important booking season for tourism to Iceland, it has affected the bookings ... only seen few requests on holiday offers since the eruption had started and ...
... Calif.) Extremely obese children have a 40 percent ... who are moderately obese have a 30 percent higher ... to a Kaiser Permanente study published online in the ... large population-based study establishes an association between obesity and ...
... ... three dental programs in the nation to receive the “Best Practice” award from Safety Net ... have translated into positive improvements for the communities they serve. , ... (Vocus) July 8, 2010 -- St. Elizabeth’s ...
... ... Patient Care , ... NY (Vocus) July 8, 2010 -- As nursing assumes an increasingly prominent role in the ... announced today it will soon require newly hired nurses to have a Bachelor of Nursing ...
... USA (July 8, 2010) To provide authors additional ... abstracts is now extended until July 31 for the ... held December 2-4 at the Washington Marriott Hotel in ... symposium on the following five topics: "Virus biology," "Pandemics, ...
Cached Medicine News:Health News:Self-Published Author Shares Her Personal Story of Hope Amidst Despair 2Health News:Iceland -- Working on its Popularity for Travellers, Iceland ProTravel Supports Ad Campaign "Inspired by Iceland" 2Health News:Iceland -- Working on its Popularity for Travellers, Iceland ProTravel Supports Ad Campaign "Inspired by Iceland" 3Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 2Health News:Extremely obese children have 40 percent higher risk of reflux disease of esophagus 3Health News:St. Elizabeth Dental Clinic Named one of the Best in the Nation 2Health News:North Shore-LIJ Becomes NY's First Health System to Require New Nurses to Get Bachelor's Degree 2Health News:North Shore-LIJ Becomes NY's First Health System to Require New Nurses to Get Bachelor's Degree 3Health News:Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: